Pharmabiz

MITM IPA-Mysuru Local Branch, JSS Pharmacy College, Mysuru & others note importance of Healthy Women –Healthy Society

MITM IPA-Mysuru Local Branch, JSS Pharmacy College, Mysuru & others note importance of Healthy Women –Healthy Society: Our ...
Pharmabiz

SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025

SystImmune & Bristol Myers Squibb announce first global phase I results of iza-bren, an EGFR x HER3 bispecific ADC, in patients with advanced solid tumours at ESMO 2025 ...
Pharmabiz

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome

Renalys Pharma reaches Japan PMDA agreement on phase III trials of sparsentan for FSGS and Alport syndrome: Tokyo, Japan Monday, October 20, 2025, 18:00 Hrs [IST] Renalys Pharma, ...
Pharmabiz

Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC

Boehringer Ingelheim’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC: Ingelheim, Germany Monday, Oc ...
Pharmabiz

Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025

Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025: Basel Monday, October 20, 2025, 15:30 Hrs [ ...
Pharmabiz

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
Pharmabiz

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty

US FDA approves expanded paediatric indications for Celltrion’s Yuflyma and unbranded adalimumab-aaty: Incheon, South Korea Monday, October 20, 2025, 17:00 Hrs [IST] Celltrion, ...
Pharmabiz

Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...
Pharmabiz

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML

EMA committee recommends marketing approval for Novartis’ Scemblix to treat adults with newly diagnosed CML: Basel Monday, October 20, 2025, 11:00 Hrs [IST] Novartis announced t ...
Pharmabiz

Biocon Biologics and Civica expand US nsulin access

Our Bureau, Bengaluru Monday, October 20, 2025, 15:20 Hrs [IST] Biocon Biologics, a global leader in biosimilars and the world ...
Pharmabiz

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event ...
Opinion
PharmabizOpinion

Cough syrup tragedy: Lessons learnt!

The Diethylene Glycol (DEG) poisoning occurred from using contaminated cough syrup has already claimed twenty four children in several states in India. The blame game continues accusing from one to ...